WO2004004698A3 - Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity - Google Patents

Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity Download PDF

Info

Publication number
WO2004004698A3
WO2004004698A3 PCT/NL2003/000501 NL0300501W WO2004004698A3 WO 2004004698 A3 WO2004004698 A3 WO 2004004698A3 NL 0300501 W NL0300501 W NL 0300501W WO 2004004698 A3 WO2004004698 A3 WO 2004004698A3
Authority
WO
WIPO (PCT)
Prior art keywords
cross
beta structure
methods
beta
formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2003/000501
Other languages
French (fr)
Other versions
WO2004004698A2 (en
Inventor
Martijn Frans Ben Gera Gebbink
Barend Bouma
Onno Wouter Kranenburg
Louise Maria Johanna Kroon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Utrecht Holding BV
Universitair Medisch Centrum Utrecht
Original Assignee
Universiteit Utrecht Holding BV
Universitair Medisch Centrum Utrecht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Utrecht Holding BV, Universitair Medisch Centrum Utrecht filed Critical Universiteit Utrecht Holding BV
Priority to DE60325381T priority Critical patent/DE60325381D1/en
Priority to NZ537495A priority patent/NZ537495A/en
Priority to DK03762927T priority patent/DK1536778T3/en
Priority to AU2003251233A priority patent/AU2003251233B2/en
Priority to EP03762927A priority patent/EP1536778B1/en
Priority to CA002492010A priority patent/CA2492010A1/en
Priority to JP2004519368A priority patent/JP2005537254A/en
Publication of WO2004004698A2 publication Critical patent/WO2004004698A2/en
Publication of WO2004004698A3 publication Critical patent/WO2004004698A3/en
Anticipated expiration legal-status Critical
Priority to US11/033,105 priority patent/US20060045853A1/en
Priority to US11/087,102 priority patent/US20070003552A1/en
Priority to US11/982,161 priority patent/US8158585B2/en
Priority to US13/437,807 priority patent/US20120189615A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9726—Tissue plasminogen activator
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)

Abstract

The invention relates to cross-beta structures and the biological role of these cross-beta structures. Methods for modulating extracellular protein degradation and/or protein clearance by dialysis or for diminishing plaques involved in conformational diseases by modulating cross-beta structure formation and/or tissue plasminogen activator (tPA)-like activity are disclosed, as well as diagnostic methods by visualising cross-beta structures.
PCT/NL2003/000501 2002-07-09 2003-07-08 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity Ceased WO2004004698A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DE60325381T DE60325381D1 (en) 2002-07-09 2003-07-08 PROTEINS BINDING THE CROSS-BETA STRUCTURE-CONTAINING AMYLOID, AND METHOD FOR MODULATING THE CROSS-BETA STRUCTURE, THEIR EDUCATION AND RELATED TOXICITY
NZ537495A NZ537495A (en) 2002-07-09 2003-07-08 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity
DK03762927T DK1536778T3 (en) 2002-07-09 2003-07-08 Proteins that bind to cross-beta structural amyloid and methods for modulating cross-beta structure, its formation and its associated toxicity
AU2003251233A AU2003251233B2 (en) 2002-07-09 2003-07-08 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity
EP03762927A EP1536778B1 (en) 2002-07-09 2003-07-08 Proteins binding to cross-beta structure comprising amyloid and methods for modulation of the cross-beta structure, its formation and its associated toxicity
CA002492010A CA2492010A1 (en) 2002-07-09 2003-07-08 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity
JP2004519368A JP2005537254A (en) 2002-07-09 2003-07-08 CROSS-β STRUCTURE COMPRISING AMYLOID-BINDING PROTEIN, METHOD FOR DETECTING CROSS-β STRUCTURE, METHOD FOR MODULATION OF CROSS-β STRUCTURE FIBRILLATION, AND METHOD FOR MODULATION OF TOXICITY TRANSPORTED BY CROSS-β STRUCTURE
US11/033,105 US20060045853A1 (en) 2002-07-09 2005-01-10 Cross-beta structure comprising amyloid-binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity
US11/087,102 US20070003552A1 (en) 2002-07-09 2005-03-21 Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
US11/982,161 US8158585B2 (en) 2002-07-09 2007-10-31 Cross-β structure comprising amyloid-binding proteins and methods for detection of the cross-β structure, for modulating cross-β structures fiber formation and modulating cross-β structure-mediated toxicity
US13/437,807 US20120189615A1 (en) 2002-07-09 2012-04-02 CROSS-ß STRUCTURE COMPRISING AMYLOID-BINDING PROTEINS AND METHODS FOR DETECTION OF THE CROSS-ß STRUCTURE, FOR MODULATING CROSS-ß STRUCTURES FIBER FORMATION AND FOR MODULATING CROSS-ß STRUCTURE-MEDIATED TOXICITY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077797.5 2002-07-09
EP02077797A EP1380290A1 (en) 2002-07-09 2002-07-09 Cross-beta structure pathway and its therapeutic relevance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/033,105 Continuation US20060045853A1 (en) 2002-07-09 2005-01-10 Cross-beta structure comprising amyloid-binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity

Publications (2)

Publication Number Publication Date
WO2004004698A2 WO2004004698A2 (en) 2004-01-15
WO2004004698A3 true WO2004004698A3 (en) 2004-06-10

Family

ID=29724525

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2003/000501 Ceased WO2004004698A2 (en) 2002-07-09 2003-07-08 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity

Country Status (13)

Country Link
US (3) US20060045853A1 (en)
EP (5) EP1380290A1 (en)
JP (1) JP2005537254A (en)
AT (1) ATE417605T1 (en)
AU (2) AU2003251233B2 (en)
CA (1) CA2492010A1 (en)
DE (1) DE60325381D1 (en)
DK (1) DK1536778T3 (en)
ES (1) ES2319982T3 (en)
NZ (2) NZ561168A (en)
PT (1) PT1536778E (en)
WO (1) WO2004004698A2 (en)
ZA (1) ZA200500062B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
EP1704867A1 (en) * 2005-03-18 2006-09-27 Crossbeta Biosciences B.V. Cross-beta structures on microbial organisms
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
AU2006267176A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
WO2007008073A2 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
BRPI0613525A2 (en) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv methods for producing an immunogenic composition, for enhancing the immunogenicity of a composition, for enhancing the immunogenicity of a vaccine composition, and for determining the amount of beta-cross structures in a vaccine composition, uses of beta-cross structures, and an immunogenic composition, subunit vaccine, and immunogenic composition
CA2645930A1 (en) * 2006-03-17 2007-09-27 Crossbeta Biosciences B.V. Methods of binding of cross-beta structures by chaperones
GB0710976D0 (en) 2007-06-07 2007-07-18 Bioalvo Am Screening method
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
CN107677828A (en) * 2008-10-31 2018-02-09 耶鲁大学 Preeclampsia detects and the method and composition for the treatment of
CA2748561C (en) 2008-12-22 2016-11-01 Kaneka Corporation A.beta. remover, a.beta. removing apparatus and a.beta. removal system
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood
DE102011003944A1 (en) 2011-02-10 2012-08-16 Oxprotect Gmbh Detection and removal of misfolded proteins / peptides
US20130122076A1 (en) * 2011-11-11 2013-05-16 Mathew Gelfand Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease
TW202019398A (en) * 2018-06-28 2020-06-01 張翔毓 Method for treating or preventing conformational diseases and drug screening method
TWI859887B (en) * 2023-05-26 2024-10-21 國立臺北科技大學 Detection method using a microscopic-type circular dichroism detection system

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0234051A1 (en) * 1986-02-17 1987-09-02 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis Tissue-type plasminogen activator mutants; recombinant genetic information coding therefor and process for preparing said mutants; their use and pharmaceutical compositions
EP0319144A1 (en) * 1987-11-06 1989-06-07 Asahi Kasei Kogyo Kabushiki Kaisha Adsorbent of beta 2-microglobulin
WO1991018610A1 (en) * 1990-05-28 1991-12-12 Olle Ljungqvist Medical Ab New use of glucose and a new solution of glucose
WO1991019488A1 (en) * 1990-06-04 1991-12-26 Therapy 2000 REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (a) BINDING INHIBITORS
EP0494848A1 (en) * 1991-01-09 1992-07-15 Pharmacia AB (reg.number 556131-9608) Method of removing endotoxins
WO1994001116A1 (en) * 1992-07-10 1994-01-20 The Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Treatment of diseases associated with amyloid formation by using congo red
WO1996039834A1 (en) * 1995-06-07 1996-12-19 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US5624908A (en) * 1993-06-11 1997-04-29 Valley Cancer Institute Antineoplastic compositions
WO1997046547A1 (en) * 1996-06-03 1997-12-11 The Texas A & M University System β-SHEET NUCLEATING PEPTIDOMIMETICS
WO1998006418A1 (en) * 1996-08-09 1998-02-19 Mannatech, Inc. Compositions of plant carbohydrates as dietary supplements
US5780615A (en) * 1992-05-21 1998-07-14 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles and diagnostic and therapeutic methods and materials derived therefrom
WO1999002545A2 (en) * 1997-07-08 1999-01-21 Novopharm Biotech Inc. Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
DE19735902A1 (en) * 1997-08-19 1999-02-25 Imtec Immundiagnostika Gmbh New selective adsorbent carrying peptide(s) that mimic complement C1q
WO1999009999A1 (en) * 1997-08-28 1999-03-04 University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
WO1999021565A1 (en) * 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Nutritional supplement for cerebral metabolic insufficiencies
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
US6001331A (en) * 1996-01-24 1999-12-14 Warner-Lambert Company Method of imaging amyloid deposits
US6037458A (en) * 1987-11-20 2000-03-14 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
WO2000059493A2 (en) * 1999-04-06 2000-10-12 Kansas University Medical Center Improved dialysis solutions and methods
US6136548A (en) * 1994-11-22 2000-10-24 Rutgers, The State University Of New Jersey Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging
WO2000068263A2 (en) * 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
WO2001007474A1 (en) * 1999-07-28 2001-02-01 Kelvin Stott Peptides containing n-substituted d-amino acids for preventing beta-strand association
WO2001012598A2 (en) * 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF
WO2001050134A2 (en) * 1999-12-29 2001-07-12 American Cyanamid Company Methods of detection of amyloidogenic proteins
WO2001058476A2 (en) * 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2001062284A2 (en) * 2000-02-21 2001-08-30 Pharmexa A/S Novel method for down-regulation of amyloid
EP1130031A1 (en) * 2000-02-25 2001-09-05 Universitair Medisch Centrum Utrecht Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
EP1179588A1 (en) * 1999-04-30 2002-02-13 Akira Matsumoto Human brain carboxypeptidase b
WO2002016333A2 (en) * 2000-08-24 2002-02-28 University Of Pittsburgh Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
US6410598B1 (en) * 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
WO2003006893A2 (en) * 2001-07-09 2003-01-23 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60103964A (en) * 1983-11-10 1985-06-08 ユニチカ株式会社 Anti-thrombotic material
US5733524A (en) 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5801200A (en) 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733933A (en) 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5700447A (en) 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5216127A (en) 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
JPH01171638A (en) * 1987-12-25 1989-07-06 Kanegafuchi Chem Ind Co Ltd Adsorbent for serum amyloid a protein
US5151082A (en) * 1988-08-05 1992-09-29 Heathdyne, Inc. Apparatus and method for kidney dialysis using plasma in lieu of blood
US5679320A (en) * 1988-12-29 1997-10-21 Bio-Technology General Corp. Fibrin binding domain polypeptides and uses and methods of producing same
CA1335361C (en) * 1989-05-24 1995-04-25 Andrei Z. Budzynski Thrombus-targeted complexes of plasminogen activator and fibrin fragments
US5180615A (en) * 1989-12-13 1993-01-19 W.R. Grace & Co.-Conn. Metallized bag for static protection of electronic components
US5591431A (en) * 1990-03-09 1997-01-07 G.D. Searle & Co. Enhancement of clot lysis
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5650418A (en) 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5278189A (en) 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5230996A (en) 1990-06-04 1993-07-27 Therapy 2000 Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5221628A (en) * 1991-03-19 1993-06-22 Northwestern University Binding of aggregated immunoglobulin or immune complexes by serum amyloid P component
US5491129A (en) * 1992-07-30 1996-02-13 Yeda Research And Development Co. Ltd. Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
DE4242736A1 (en) * 1992-12-17 1994-06-23 Behringwerke Ag Synthetic peptides, antibodies against them and their use
US5955343A (en) * 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
ATE239797T1 (en) * 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd ANTIBODIES TO BETA-AMYLOID OR DERIVATIVES THEREOF AND THEIR USE
JP3680114B2 (en) * 1993-09-17 2005-08-10 敏一 中村 Cranial nerve disorder treatment
EP0689843B1 (en) * 1993-12-17 2003-09-10 Mochida Pharmaceutical Co., Ltd. Composition containing soluble thrombomodulins
AU692237B2 (en) 1994-02-03 1998-06-04 Picower Institute For Medical Research, The Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
KR0163563B1 (en) * 1994-03-23 1998-12-01 김종인 Topical drug in combination for treatment of skin lesions
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US5854204A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US6436969B1 (en) 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
EP0882139A1 (en) * 1995-10-02 1998-12-09 Mohammed W. Katoot Biologically-active polymers
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6310046B1 (en) * 1995-11-17 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Sequestrin of Plasmodium falciparum
US5785187A (en) * 1996-04-29 1998-07-28 Lipman; Daniel Mechandising display assembly
US6929807B1 (en) * 1996-08-09 2005-08-16 Mannatech, Inc. Compositions of plant carbohydrates as dietary supplements
US6689275B1 (en) * 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
US6372473B1 (en) * 1997-05-28 2002-04-16 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
US20020122807A1 (en) 1998-07-07 2002-09-05 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
WO1999047072A1 (en) * 1998-03-18 1999-09-23 Tyndale Plains-Hunter, Ltd. Hydrophilic polyether polyurethanes containing carboxylic acid
JP4037525B2 (en) 1998-03-25 2008-01-23 生化学工業株式会社 New antibacterial peptide
US7041287B2 (en) * 1998-05-21 2006-05-09 Trustees Of The University Of Pennsylvania Compositions and methods for selective dissolution of nascent intravascular blood clots
WO2000009562A1 (en) 1998-08-12 2000-02-24 The New York Blood Center, Inc. Novel cleaved fragments of fibrinogen
EP1115396A4 (en) * 1998-09-25 2002-05-22 Sunol Molecular Corp Pharmaceutically active compounds and methods of use thereof
IN190822B (en) * 1998-12-24 2003-08-23 Council Scient Ind Res
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6161547A (en) * 1999-01-15 2000-12-19 Coaxia, Inc. Medical device for flow augmentation in patients with occlusive cerebrovascular disease and methods of use
AT500670A1 (en) * 1999-05-19 2006-02-15 Bio & Bio Licensing Sa DRUGS FOR LOCAL APPLICATION
AU780474B2 (en) * 1999-06-16 2005-03-24 Boston Biomedical Research Institute Incorporated Immunological control of beta-amyloid levels in vivo
US20040013647A1 (en) * 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6576627B1 (en) * 1999-09-14 2003-06-10 Meiji Seika Kaisha Ltd. Phosphonic acid derivatives having carboxypeptidase b inhibitory activity
EP1252181B1 (en) 2000-01-20 2006-01-18 Regents Of The University Of Minnesota Peptides with antibacterial activity
AU783144B2 (en) * 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
AU2001247667A1 (en) * 2000-03-21 2001-10-03 Research Foundation Of State University Of New York Adsorption of polyampholytes to charged surfaces and assays incorporating same
DE10017690A1 (en) * 2000-04-08 2001-10-25 Simmoteit Robert Device for mass exchange and cultivation of cells
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
EP1186299A1 (en) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
AU2002211517A1 (en) * 2000-10-04 2002-04-15 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
DE60032250T2 (en) * 2000-12-28 2007-03-15 Biomay Produktions- Und Handels-Aktiengesellschaft Treatment of allergies
EP1383885A4 (en) * 2001-04-04 2005-11-30 American Diagnostica Inc Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof
EP1395833B1 (en) 2001-05-31 2013-02-27 Adlyfe, Inc. Misfolded protein sensor method
US6960465B1 (en) * 2001-06-27 2005-11-01 Northwestern University Increased cell resistance to toxic organic substances
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
JP2003024080A (en) * 2001-07-19 2003-01-28 Univ Tokyo Screening method for p53-dependent apoptosis-inducing protein and apoptosis regulator
GB0202275D0 (en) 2002-01-31 2002-03-20 Hansa Medica Ab Peptide
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
WO2003073106A2 (en) 2002-02-28 2003-09-04 Microsens Biophage Limited Binding of pathological forms of prion proteins
EP1507543A4 (en) * 2002-05-09 2006-07-26 Cambridgemed Inc A pharmaceutical composition for treatment of wounds containing blood plasma or serum
EP1380290A1 (en) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
US20050142611A1 (en) * 2002-09-30 2005-06-30 Auburn University Method of isolation and self-assembly of small protein particles from blood and other biological materials
US7470667B2 (en) * 2002-12-05 2008-12-30 Medgenn (Hong Kong) Ltd Methods of treating cancer using a modified endostatin protein
EP1449536A1 (en) 2003-02-14 2004-08-25 Prionics AG Prion proteins (PrP) as therapeutic agents for the treatment of AP-1 associated diseases
WO2004073651A2 (en) * 2003-02-18 2004-09-02 The Ohio State University Research Foundation Identifying inhibitors of intracellular protein fibrillization
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
US7427659B2 (en) 2003-10-24 2008-09-23 Amgen Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
US20090156471A1 (en) 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
WO2006091038A1 (en) * 2005-02-25 2006-08-31 Medigenes Co., Ltd. Pharmaceutical composition for treating avellino cornea dystrophy comprising blood plasma or serum
EP1704867A1 (en) * 2005-03-18 2006-09-27 Crossbeta Biosciences B.V. Cross-beta structures on microbial organisms
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
BRPI0613525A2 (en) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv methods for producing an immunogenic composition, for enhancing the immunogenicity of a composition, for enhancing the immunogenicity of a vaccine composition, and for determining the amount of beta-cross structures in a vaccine composition, uses of beta-cross structures, and an immunogenic composition, subunit vaccine, and immunogenic composition
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
WO2007008073A2 (en) 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF
AU2006267176A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
JP2009504636A (en) 2005-08-11 2009-02-05 メディジーンズ カンパニー リミテッド Pharmaceutical composition for treatment of nerve injury comprising plasma or serum
US8543424B2 (en) * 2005-12-30 2013-09-24 Darryl Mark Hunsaker Vehicle insurance status display system
CA2645930A1 (en) * 2006-03-17 2007-09-27 Crossbeta Biosciences B.V. Methods of binding of cross-beta structures by chaperones
ES2599319T3 (en) 2006-06-26 2017-02-01 Macrogenics, Inc. Fc RIIB specific antibodies and their methods of use
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens

Patent Citations (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0234051A1 (en) * 1986-02-17 1987-09-02 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis Tissue-type plasminogen activator mutants; recombinant genetic information coding therefor and process for preparing said mutants; their use and pharmaceutical compositions
EP0319144A1 (en) * 1987-11-06 1989-06-07 Asahi Kasei Kogyo Kabushiki Kaisha Adsorbent of beta 2-microglobulin
US6037458A (en) * 1987-11-20 2000-03-14 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
WO1991018610A1 (en) * 1990-05-28 1991-12-12 Olle Ljungqvist Medical Ab New use of glucose and a new solution of glucose
WO1991019488A1 (en) * 1990-06-04 1991-12-26 Therapy 2000 REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (a) BINDING INHIBITORS
EP0494848A1 (en) * 1991-01-09 1992-07-15 Pharmacia AB (reg.number 556131-9608) Method of removing endotoxins
US5780615A (en) * 1992-05-21 1998-07-14 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles and diagnostic and therapeutic methods and materials derived therefrom
WO1994001116A1 (en) * 1992-07-10 1994-01-20 The Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Treatment of diseases associated with amyloid formation by using congo red
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
US5624908A (en) * 1993-06-11 1997-04-29 Valley Cancer Institute Antineoplastic compositions
US6410598B1 (en) * 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US6136548A (en) * 1994-11-22 2000-10-24 Rutgers, The State University Of New Jersey Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging
WO1996039834A1 (en) * 1995-06-07 1996-12-19 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US6001331A (en) * 1996-01-24 1999-12-14 Warner-Lambert Company Method of imaging amyloid deposits
WO1997046547A1 (en) * 1996-06-03 1997-12-11 The Texas A & M University System β-SHEET NUCLEATING PEPTIDOMIMETICS
WO1998006418A1 (en) * 1996-08-09 1998-02-19 Mannatech, Inc. Compositions of plant carbohydrates as dietary supplements
WO1999002545A2 (en) * 1997-07-08 1999-01-21 Novopharm Biotech Inc. Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
DE19735902A1 (en) * 1997-08-19 1999-02-25 Imtec Immundiagnostika Gmbh New selective adsorbent carrying peptide(s) that mimic complement C1q
WO1999009999A1 (en) * 1997-08-28 1999-03-04 University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
WO1999021565A1 (en) * 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Nutritional supplement for cerebral metabolic insufficiencies
WO2000059493A2 (en) * 1999-04-06 2000-10-12 Kansas University Medical Center Improved dialysis solutions and methods
EP1179588A1 (en) * 1999-04-30 2002-02-13 Akira Matsumoto Human brain carboxypeptidase b
WO2000068263A2 (en) * 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
WO2001007474A1 (en) * 1999-07-28 2001-02-01 Kelvin Stott Peptides containing n-substituted d-amino acids for preventing beta-strand association
WO2001012598A2 (en) * 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF
WO2001050134A2 (en) * 1999-12-29 2001-07-12 American Cyanamid Company Methods of detection of amyloidogenic proteins
US6399314B1 (en) * 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
WO2001058476A2 (en) * 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2001062284A2 (en) * 2000-02-21 2001-08-30 Pharmexa A/S Novel method for down-regulation of amyloid
EP1130031A1 (en) * 2000-02-25 2001-09-05 Universitair Medisch Centrum Utrecht Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
WO2002016333A2 (en) * 2000-08-24 2002-02-28 University Of Pittsburgh Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
WO2003006893A2 (en) * 2001-07-09 2003-01-23 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BRONSVELD W ET AL: "Use of glucose-insulin-potassium (GIK) in human septic shock.", CRITICAL CARE MEDICINE, (1985 JUL) 13 (7) 566-70., XP008011134 *
CARDOSO I ET AL: "Aprotinin binding to amyloid fibrils.", EUROPEAN JOURNAL OF BIOCHEMISTRY / FEBS. GERMANY APR 2000, vol. 267, no. 8, April 2000 (2000-04-01), pages 2307 - 2311, XP001128718, ISSN: 0014-2956 *
CHAUHAN VED P S ET AL: "Metal cations defibrillize the amyloid beta-protein fibrils.", NEUROCHEMICAL RESEARCH, vol. 22, no. 7, 1997, pages 805 - 809, XP008011139, ISSN: 0364-3190 *
J. REINBOLD, OFTERSHEIM: "Wenn der "Zucker" entgleist - Akuttherapie der diabetischen Notfälle", NOTFALLMEDIZIN, vol. 28, February 2002 (2002-02-01), pages 82 - 84, XP008011142 *
JACKSON R L ET AL: "Glucose infusions increase plasma levels of amyloid proteins in high density lipoproteins.", BIOMEDICINE, (1980 DEC) 33 (8) 245., XP008011135 *
KOROL D L ET AL: "GLUCOSE. MEMORY, AND AGING", AMERICAN JOURNAL OF CLINICAL NUTRITION, BETHESDA,MD, US, vol. 67, no. 6, April 1998 (1998-04-01), pages 764S - 771S, XP000951458, ISSN: 0002-9165 *
KRANENBURG ONNO ET AL: "Tissue-type plasminogen activator is a multiligand cross-beta structure receptor.", CURRENT BIOLOGY, vol. 12, no. 21, 29 October 2002 (2002-10-29), pages 1833 - 1839, XP001172448, ISSN: 0960-9822 (ISSN print) *
MAGGIO JOHN E ET AL: "Brain amyloid: A physicochemical perspective.", BRAIN PATHOLOGY, vol. 6, no. 2, 1996, pages 147 - 162, XP008011141, ISSN: 1015-6305 *
PEPYS M B: "Pathogenesis, diagnosis and treatment of systemic amyloidosis.", PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON B BIOLOGICAL, vol. 356, no. 1406, 2001, 28 February, 2001, pages 203 - 211, XP008011132, ISSN: 0962-8436 *
SOTO C ET AL: "BETA-SHEET BREAKER PEPTIDES INHIBIT FIBRILLOGENESIS IN A RAT BRAIN MODEL OF AMYLOIDOSIS: IMPLICATIONS FOR ALZHEIMER'S THERAPY", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 7, 1998, pages 822 - 826, XP000914747, ISSN: 1078-8956 *
SUNDE M ET AL: "Common core structure of amyloid fibrils by synchrotron X-ray diffraction", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 273, no. 3, 31 October 1997 (1997-10-31), pages 729 - 739, XP004453904, ISSN: 0022-2836 *
TESTA I ET AL: "The effect of different glucose endovenous administrations on amylin and insulin blood concentration in healthy subjects.", BOLLETTINO - SOCIETA ITALIANA BIOLOGIA SPERIMENTALE, (1996 MAR-APR) 72 (3-4) 103-8., XP008011133 *
WASTERLAIN C G ET AL: "Status epilepticus in immature rats. Protective effects of glucose on survival and brain development.", ARCHIVES OF NEUROLOGY. UNITED STATES DEC 1976, vol. 33, no. 12, December 1976 (1976-12-01), pages 831 - 837, XP008011138, ISSN: 0003-9942 *
YUTANI KATSUHIDE ET AL: "The process of amyloid-like fibril formation by methionine aminopeptidase from a hyperthermophile, Pyrococcus furiosus.", BIOCHEMISTRY, vol. 39, no. 10, 14 March 2000 (2000-03-14), pages 2769 - 2777, XP001128143, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
PT1536778E (en) 2009-03-24
EP1978362A3 (en) 2009-02-11
EP2341348A1 (en) 2011-07-06
WO2004004698A2 (en) 2004-01-15
EP1978362A2 (en) 2008-10-08
CA2492010A1 (en) 2004-01-15
ES2319982T3 (en) 2009-05-18
AU2003251233A1 (en) 2004-01-23
AU2010200343A1 (en) 2010-02-18
US20060045853A1 (en) 2006-03-02
ATE417605T1 (en) 2009-01-15
DK1536778T3 (en) 2009-04-14
NZ537495A (en) 2009-04-30
ZA200500062B (en) 2005-11-01
EP2322154A2 (en) 2011-05-18
JP2005537254A (en) 2005-12-08
US20080241165A1 (en) 2008-10-02
DE60325381D1 (en) 2009-01-29
US8158585B2 (en) 2012-04-17
NZ561168A (en) 2009-06-26
EP1380290A1 (en) 2004-01-14
EP2322154A3 (en) 2011-10-05
US20120189615A1 (en) 2012-07-26
EP1536778B1 (en) 2008-12-17
EP1536778A2 (en) 2005-06-08
AU2003251233B2 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
WO2004004698A3 (en) Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
WO2003057134A8 (en) Specific binding agents of human angiopoietin-2
DE60128916D1 (en) NEW, PHYSIOLOGICALLY ACTIVE PEPTIDE AND ITS USE
UA107490C2 (en) TNF-α-Binding Protein
WO2003087831A3 (en) Proteins involved in breast cancer
WO2007064881A3 (en) Implantable microbial cellulose materials for various medical applications
EP2361934A3 (en) Hepatocyte growth factor (HGF) binding proteins
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2006050058A3 (en) Methods of detection and therapy of inflamed tissues using immune modulation
WO2002053774A3 (en) Method for determining homeostasis of the skin
ATE549353T1 (en) ACTIVE VARIANTS OF IL-18 BINDING PROTEIN AND THEIR MEDICAL USES
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2008003707A3 (en) Minimized small peptides with high affinity for factor viii and factor viii-like proteins
WO2004042083A3 (en) Nucleic acid ligands and uses therefor
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2004085614A3 (en) Nucleic acid molecules that are differentially regulated in a bipolar disorder and uses thereof
WO2003087840A3 (en) Protein involved in cancer
WO2005004894A3 (en) Methods for increasing cell and tissue viability
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
WO2006046134A3 (en) Method of screening by using conformation sensitive peptides
WO2004035783A3 (en) Protein complexes of the tumor-necrosis-factor-alpha (tnf-alpha) signalling pathway
WO2008021211A3 (en) Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003251233

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005/00062

Country of ref document: ZA

Ref document number: 200500062

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 537495

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2492010

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11033105

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004519368

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003762927

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003762927

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11033105

Country of ref document: US